Brittany Cote

Articles

PROfound Trial With Olaparib Shows Feasibility of Personalizing Care in mCRPC

October 15th 2020

Maha H.A. Hussain, MD, FACP, FASCO, discusses the updated findings from the PROfound trial, its clinical significance in the treatment of patients with mCRPC paradigm, and the promise of precision medicine.

Research Efforts Abound as the Role of BTK Inhibitors Continues to Evolve in CLL

October 14th 2020

Erlene  Seymour, MD, discusses BTK inhibitors and how they have shifted the standard of care for the frontline treatment of patients with chronic lymphocytic leukemia.

CD38-Directed Regimens Lead the Pack in Relapsed/Refractory Myeloma Treatment

October 12th 2020

Rebecca Silbermann, MD, MMS, discusses combinations featuring the monoclonal antibodies daratumumab or isatuximab-irfc and how they have made notable differences in outcomes for patients with relapsed/refractory multiple myeloma.

PD-1/CTLA-4 Combos, Broader Patient Population Are Next Steps With Immunotherapy in Locally Advanced NSCLC

October 12th 2020

David Gerber, MD, highlights the impact of the PACIFIC trial and other next steps with immunotherapy in patients with stage III NSCLC.

Identifying Genetic Variants, Matching With Targeted Therapies Serve as Next Great Challenge With Germline Testing in Oncology

October 12th 2020

Goutham Narla, MD, PhD, discusses the revolution of genetic testing and how it has led to more accurate and widespread assays for patients with cancer.

Patient Advocacy and Education Are Essential for Optimal Cancer Care

October 11th 2020

Caroline Farrington, PhD, shares her insight as both a researcher and a cancer survivor on the importance of patient advocacy, as well as the proper resources to aid patients through a cancer diagnosis.

Focusing on the Future of Genetic Testing in Oncology

October 10th 2020

John M. Carethers, MD, MACP, discusses recent developments in multi-gene panel testing.

Sequencing Debate for Frontline BRAF-Mutant Melanoma in Full Force

October 8th 2020

Geoffrey T. Gibney, MD, provides an update on the evolution of frontline treatment in metastatic melanoma.

Next Steps in Small Cell Lung Cancer Feature Closer Eye on Immunotherapy, Lurbinectedin

October 8th 2020

Benjamin Drapkin, MD, PhD, discusses the road ahead in small cell lung cancer research, and the challenges that still need to be solved in the first- and second-line settings.

Choueiri Highlights Efficacy of Cabozantinib/Nivolumab in RCC, Next Steps for Research

October 7th 2020

Toni Choueiri, MD, discusses the CheckMate-9ER trial, the next steps for nivolumab/cabozantinib, and other cabozantinib regimens under exploration.

Nivolumab/Ipilimumab Elicits Durable Responses in Refractory Advanced RCC

October 6th 2020

Scott Tykodi, MD, PhD, discusses the FRACTION-RCC study and other novel combinations under exploration for heavily pretreated patients with advanced renal cell carcinoma.

Stoffel Underscores Importance of Germline Testing for Lynch Syndrome

October 2nd 2020

Elena M. Stoffel, MD, MPH, discusses the importance of genetic testing in detecting Lynch syndrome and other hereditary syndromes associated with risk of colorectal cancer and other diseases.

Regorafenib/Nivolumab Shows Modest Activity in MMR Proficient Advanced Refractory CRC

October 1st 2020

Richard D. Kim, MD, discusses the potential of regorafenib plus nivolumab in patients with advanced colorectal cancer and the need for biomarkers to predict response to the regimen.

Selinexor May Offer Post–CAR T Potential in Relapsed/Refractory DLBCL

September 30th 2020

Kami Maddocks, MD, discusses the significance of the selinexor approval in the diffuse large B-cell lymphoma treatment paradigm, emerging strategies that seek to address unmet needs, and remaining sequencing questions.

Maintenance PARP Yields Impressive PFS Benefit in Recurrent, Platinum-Sensitive Ovarian Cancer

September 30th 2020

Amanda L. Jackson, MD, , discusses the role of PARP inhibitors in the maintenance treatment of patients with recurrent platinum-sensitive ovarian cancer.

Oyer Underscores Importance of Innovation and Collaboration in Cancer Care

September 25th 2020

Randall A. Oyer, MD, shares key highlights from the Association of Community Cancer Centers National Oncology Conference, the future of virtual meetings in light of the coronavirus disease 2019 pandemic, and innovative efforts dedicated to improving cancer care.

BCMA-Targeted Approaches Revolutionize Relapsed/Refractory Myeloma Treatment

September 24th 2020

Elisabet E. Manasanch, MD, discusses novel BCMA-targeted modalities that are emerging in relapsed/refractory multiple myeloma.

Triplet Regimens Dominate the Relapsed/Refractory Myeloma Treatment Landscape

September 22nd 2020

Kelly Godby, MD, discusses novel triplet combinations and how they are leading the key developments made in the treatment of patients with relapsed/refractory multiple myeloma in recent years.

Novel Triplet Combos Offer Deep Remissions in Relapsed/Refractory Multiple Myeloma

September 16th 2020

Joshua Richter, MD, discusses the importance of optimizing these novel therapies to make way for precision medicine in multiple myeloma.

Oncotype DX GPS Test Shows Predictive Benefit in Unfavorable Intermediate-Risk Prostate Cancer

September 14th 2020

Jennifer Cullen, MPH, PhD, discusses the genomic test as a predictor of outcomes in patients with unfavorable intermediate-risk prostate cancer and next steps for research.